Fig. 3

Kaplan-Meier analyses of pre-treatment samples. a, c, e Progression-free survival and b, d, f overall survival are shown for a, b patients with short (≤ 167 bp) vs those with long (> 167 bp) cfDNA fragment size; c, d patients with high vs those with low cfDNA levels, and e, f patients positive for two markers, vs those with one or no markers